Folic acid-induced nephropathy model for hyperoside renoprotection

Validation Score: 0.900 Price: $0.50 chronic kidney disease folic acid-induced nephropathy mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting ACAT1 in folic acid-induced nephropathy mice. Primary outcome: reduction in renal fibrosis and mitochondrial injury

Description

Mouse model of chronic kidney disease was established using folic acid administration to induce nephropathy. Mice were treated with hyperoside to evaluate its renoprotective effects against kidney fibrosis. The study assessed mitochondrial function, lipid metabolism, and fibrotic progression through histological evaluation, biochemical analyses, and electron microscopy. Multi-omics approaches including transcriptomics and metabolomics were employed to characterize metabolic pathway modulation by hyperoside treatment.

TARGET GENE
ACAT1
MODEL SYSTEM
folic acid-induced nephropathy mice
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
fatty acid oxidation, ketone body metabolism, ACAT1-l-carnitine-SIRT3 axis
SOURCE
extracted_from_pmid_41903436
PRIMARY OUTCOME
reduction in renal fibrosis and mitochondrial injury

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.900 composite

📖 Wiki Pages

Mitochondriaentity

Protocol

folic acid administration to induce nephropathy, hyperoside treatment, histological evaluation, biochemical analyses, electron microscopy, transcriptomic and metabolomic analyses

Expected Outcomes

hyperoside would reduce renal fibrosis and improve mitochondrial function

Success Criteria

significant reduction in fibrotic markers and improved mitochondrial morphology and function

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.